{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:36Z","timestamp":1761101016757,"version":"3.37.0"},"reference-count":20,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2009,7,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Thalidomide-dexamethasone (THAL-DEX) is standard induction therapy for multiple myeloma (MM). Tandem melphalan-based transplantations have yielded superior results to single transplantations. Phase II trial S0204 was designed to improve survival results reported for the predecessor, phase III trial S9321 by 50%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Newly diagnosed patients with MM were eligible for S0204 with THAL-DEX induction, tandem melphalan-based tandem transplantation, and THAL-prednisone maintenance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 143 eligible patients, 142 started induction, 73% completed first transplantation, 58% completed second transplantation, and 56% started maintenance. The quantity of stem cells required for two transplantations was reached in 88% of 111 patients undergoing collection, 74% of whom completed both transplantations. Partial response, very good partial remission, and complete response were documented after 12 months of maintenance therapy in 87%, 72%, and 22% of patients, respectively. During a median follow-up time of 37 months, 4-year estimates of event-free and overall survival were 50% and 64%, respectively. Survival outcomes were superior for International Staging System (ISS) stage 1 disease, when lactate dehydrogenase (LDH) levels were normal and a second transplantation was applied in a timely fashion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both overall survival (P = .0002) and event-free survival (P &lt; .0001) were significantly improved with S0204 compared with S9321 when 121 and 363 patients, respectively, were matched on ISS stage and LDH.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2008.19.9240","type":"journal-article","created":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T01:56:20Z","timestamp":1245722180000},"page":"3510-3517","source":"Crossref","is-referenced-by-count":19,"title":["Phase II Study of Thalidomide Plus Dexamethasone Induction Followed by Tandem Melphalan-Based Autotransplantation and Thalidomide-Plus-Prednisone Maintenance for Untreated Multiple Myeloma: A Southwest Oncology Group Trial (S0204)"],"prefix":"10.1200","volume":"27","author":[{"given":"Mohamad A.","family":"Hussein","sequence":"first","affiliation":[{"name":"From the H. Lee Moffitt Cancer and Research Center, Tampa, FL; Southwest Oncology Group Biostatistical Center, Seattle, WA; Wayne State University Karmanos Cancer Institute, Detroit; and University of Michigan Medical Center, Ann Arbor, MI; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; and University of Arkansas for Medical Sciences, Little Rock, AR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Bolejack","sequence":"additional","affiliation":[{"name":"From the H. Lee Moffitt Cancer and Research Center, Tampa, FL; Southwest Oncology Group Biostatistical Center, Seattle, WA; Wayne State University Karmanos Cancer Institute, Detroit; and University of Michigan Medical Center, Ann Arbor, MI; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; and University of Arkansas for Medical Sciences, Little Rock, AR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Zonder","sequence":"additional","affiliation":[{"name":"From the H. Lee Moffitt Cancer and Research Center, Tampa, FL; Southwest Oncology Group Biostatistical Center, Seattle, WA; Wayne State University Karmanos Cancer Institute, Detroit; and University of Michigan Medical Center, Ann Arbor, MI; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; and University of Arkansas for Medical Sciences, Little Rock, AR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.M.","family":"Durie","sequence":"additional","affiliation":[{"name":"From the H. Lee Moffitt Cancer and Research Center, Tampa, FL; Southwest Oncology Group Biostatistical Center, Seattle, WA; Wayne State University Karmanos Cancer Institute, Detroit; and University of Michigan Medical Center, Ann Arbor, MI; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; and University of Arkansas for Medical Sciences, Little Rock, AR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"From the H. Lee Moffitt Cancer and Research Center, Tampa, FL; Southwest Oncology Group Biostatistical Center, Seattle, WA; Wayne State University Karmanos Cancer Institute, Detroit; and University of Michigan Medical Center, Ann Arbor, MI; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; and University of Arkansas for Medical Sciences, Little Rock, AR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Crowley","sequence":"additional","affiliation":[{"name":"From the H. Lee Moffitt Cancer and Research Center, Tampa, FL; Southwest Oncology Group Biostatistical Center, Seattle, WA; Wayne State University Karmanos Cancer Institute, Detroit; and University of Michigan Medical Center, Ann Arbor, MI; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; and University of Arkansas for Medical Sciences, Little Rock, AR."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"From the H. Lee Moffitt Cancer and Research Center, Tampa, FL; Southwest Oncology Group Biostatistical Center, Seattle, WA; Wayne State University Karmanos Cancer Institute, Detroit; and University of Michigan Medical Center, Ann Arbor, MI; Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; and University of Arkansas for Medical Sciences, Little Rock, AR."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.5807"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.3.789"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032290"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053583"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145235"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0221"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.3077.3077"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"B13","first-page":"163","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Chemotherapy Reports"},{"key":"B14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"Cox DR","year":"1972","journal-title":"J Royal Statistical Soc B"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2007.09.006"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022962"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101212"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-127704"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06921.x"},{"journal-title":"Am Soc Hematol","author":"Barlogie B","key":"B20"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.19.9240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T08:17:58Z","timestamp":1739175478000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.19.9240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,20]]},"references-count":20,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2009,7,20]]}},"alternative-id":["10.1200\/JCO.2008.19.9240"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.19.9240","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"subject":[],"published":{"date-parts":[[2009,7,20]]}}}